Recent Insight into the Role of Sphingosine-1-Phosphate Lyase in Neurodegeneration
暂无分享,去创建一个
[1] Younghun Jung,et al. Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer’s disease , 2022, Brain Research.
[2] G. Semenkova,et al. 2-Hexadecenal Regulates ROS Production and Induces Apoptosis in Polymorphonuclear Leucocytes , 2022, Cell Biochemistry and Biophysics.
[3] T. Ziemssen,et al. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more , 2022, Expert opinion on drug metabolism & toxicology.
[4] A. Armirotti,et al. Treatment with THI, an inhibitor of Sphingosine-1-phosphate Lyase (SGPL1), modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington's disease. , 2022, Molecular Therapy.
[5] M. Lasaga,et al. Neuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia , 2021, Current neuropharmacology.
[6] J. Matías‐Guiu,et al. A Transcriptomic Meta-Analysis Shows Lipid Metabolism Dysregulation as an Early Pathological Mechanism in the Spinal Cord of SOD1 Mice , 2021, International journal of molecular sciences.
[7] F. Schumacher,et al. Nuclear Sphingosine-1-phosphate Lyase Generated ∆2-hexadecenal is A Regulator of HDAC Activity and Chromatin Remodeling in Lung Epithelial Cells , 2021, Cell Biochemistry and Biophysics.
[8] T. Hornemann,et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis , 2021, Nature Medicine.
[9] C. Gerloff,et al. Sphingosine‐1‐Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK‐PD) , 2021, Movement disorders : official journal of the Movement Disorder Society.
[10] L. McCullough,et al. The Functional Role of Sphingosine Kinase 2 , 2021, Frontiers in Molecular Biosciences.
[11] Guojie Yang,et al. Bone marrow mesenchymal stem cells‐derived exosomes reduce Aβ deposition and improve cognitive function recovery in mice with Alzheimer's disease by activating sphingosine kinase/sphingosine‐1‐phosphate signaling pathway , 2020, Cell biology international.
[12] E. Dardiotis,et al. Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease , 2020, International journal of molecular sciences.
[13] G. van Echten-Deckert,et al. Neurodegeneration Caused by S1P-Lyase Deficiency Involves Calcium-Dependent Tau Pathology and Abnormal Histone Acetylation , 2020, Cells.
[14] C. Guatimosim,et al. Inflammation in Huntington's disease: A few new twists on an old tale , 2020, Journal of Neuroimmunology.
[15] A. Hołownia,et al. Pharmacological inhibition of sphingosine-1-phosphate lyase partially reverses spatial memory impairment in streptozotocin-diabetic rats , 2020, Molecular and Cellular Neuroscience.
[16] P. Bruni,et al. Sphingosine 1-phosphate lyase blockade elicits myogenic differentiation of murine myoblasts acting via Spns2/S1P2 receptor axis. , 2020, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[17] R. Schneiter,et al. Mitochondrial sphingosine-1-phosphate lyase is essential for phosphatidylethanolamine synthesis and survival of Trypanosoma brucei , 2020, Scientific Reports.
[18] L. Metherell,et al. A Sphingosine-1-Phosphate Lyase Mutation Associated With Congenital Nephrotic Syndrome and Multiple Endocrinopathy , 2020, Frontiers in Pediatrics.
[19] L. Walensky,et al. Site-Dependent Cysteine Lipidation Potentiates the Activation of Proapoptotic BAX , 2020, Cell reports.
[20] G. Massicotte,et al. Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson’s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model , 2020, Frontiers in Pharmacology.
[21] J. Pfeilschifter,et al. Downregulation of S1P Lyase Improves Barrier Function in Human Cerebral Microvascular Endothelial Cells Following an Inflammatory Challenge , 2020, International journal of molecular sciences.
[22] L. Metherell,et al. Sphingosine-1-phosphate lyase (SGPL1) deficiency is associated with mitochondrial dysfunction , 2018, The Journal of Steroid Biochemistry and Molecular Biology.
[23] E. Clambey,et al. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation. , 2019, Inflammatory bowel diseases.
[24] T. Fath,et al. Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease , 2019, The Journal of Neuroscience.
[25] Sean J. Humphrey,et al. Sphingosine 1‐phosphate but not Fingolimod protects neurons against excitotoxic cell death by inducing neurotrophic gene expression in astrocytes , 2019, Journal of neurochemistry.
[26] A. Lebedev,et al. Changes in the Metabolism of Sphingoid Bases in the Brain and Spinal Cord of Transgenic FUS(1-359) Mice, a Model of Amyotrophic Lateral Sclerosis , 2019, Biochemistry (Moscow).
[27] I. Glezer,et al. Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis , 2019, Scientific Reports.
[28] K. Setchell,et al. Disarranged Sphingolipid Metabolism From Sphingosine-1-Phosphate Lyase Deficiency Leads to Congenital Nephrotic Syndrome , 2019, Kidney international reports.
[29] B. Levkau,et al. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. , 2019, Bone.
[30] G. van Echten-Deckert,et al. Neural sphingosine 1‐phosphate accumulation activates microglia and links impaired autophagy and inflammation , 2019, Glia.
[31] E. Amico,et al. Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model , 2019, Front. Mol. Neurosci..
[32] J. Chun,et al. Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. , 2019, Annual review of pharmacology and toxicology.
[33] Youn-Jeong Choi,et al. Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism. , 2019, Advances in biological regulation.
[34] A. Baer,et al. Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways , 2018, Scientific Reports.
[35] P. Kosson,et al. Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase , 2018, Neuropharmacology.
[36] L. Weber,et al. A novel mutation in sphingosine-1-phosphate lyase causing congenital brain malformation , 2018, Brain and Development.
[37] W. Lukiw,et al. Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer’s Disease , 2018, Molecular Neurobiology.
[38] A. Bereket,et al. Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency , 2018, BMC Neurology.
[39] A. di Pardo,et al. Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders , 2018, Front. Neurosci..
[40] C. Duyckaerts,et al. Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain , 2018, Acta neuropathologica communications.
[41] M. Spedding,et al. Sphingolipid Metabolism Is Dysregulated at Transcriptomic and Metabolic Levels in the Spinal Cord of an Animal Model of Amyotrophic Lateral Sclerosis , 2018, Front. Mol. Neurosci..
[42] S. Pena,et al. Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1 , 2017, Clinical kidney journal.
[43] E. Amico,et al. De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease , 2017, Front. Neurosci..
[44] P. Greengard,et al. Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements , 2017, Nature Communications.
[45] M. D'Esposito,et al. Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease , 2017, Scientific Reports.
[46] F. Schumacher,et al. The sphingosine 1-phosphate breakdown product, (2E)-hexadecenal, forms protein adducts and glutathione conjugates in vitro[S] , 2017, Journal of Lipid Research.
[47] N. Putluri,et al. Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease , 2017, Human molecular genetics.
[48] Y. Frishberg,et al. Deficiency of the sphingosine‐1‐phosphate lyase SGPL1 is associated with congenital nephrotic syndrome and congenital adrenal calcifications , 2017, Human mutation.
[49] J. Pfeilschifter,et al. Characterization of cholesterol homeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts reveals a Niemann-Pick disease type C-like phenotype with enhanced lysosomal Ca2+ storage , 2017, Scientific Reports.
[50] K. Schwarz,et al. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency , 2017, The Journal of clinical investigation.
[51] G. van Echten-Deckert,et al. SGPL1 (sphingosine phosphate lyase 1) modulates neuronal autophagy via phosphatidylethanolamine production , 2017, Autophagy.
[52] T. Hornemann,et al. Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth neuropathy , 2017, Neurology.
[53] L. Metherell,et al. Sphingosine-1-phosphate lyase mutations cause primary adrenal insufficiency and steroid-resistant nephrotic syndrome , 2017, The Journal of clinical investigation.
[54] I. Bjelobaba,et al. Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies. , 2017, Current pharmaceutical design.
[55] Yuqin Ye,et al. Activation of Sphingosine 1-Phosphate Receptor 1 Enhances Hippocampus Neurogenesis in a Rat Model of Traumatic Brain Injury: An Involvement of MEK/Erk Signaling Pathway , 2016, Neural plasticity.
[56] O. Shupliakov,et al. Sphingosine 1-phosphate lyase ablation disrupts presynaptic architecture and function via an ubiquitin- proteasome mediated mechanism , 2016, Scientific Reports.
[57] D. B. Duignan,et al. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats , 2016, The Journal of Pharmacology and Experimental Therapeutics.
[58] O. Dzyubachyk,et al. Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931. , 2016, American journal of physiology. Lung cellular and molecular physiology.
[59] N. Hemdan,et al. Modulating sphingosine 1‐phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis , 2016, European journal of immunology.
[60] Ernest Fraenkel,et al. Revealing disease-associated pathways by network integration of untargeted metabolomics , 2016, Nature Methods.
[61] Kendra D Bunner,et al. Corticostriatal Dysfunction in Huntington’s Disease: The Basics , 2016, Front. Hum. Neurosci..
[62] T. Kodadek,et al. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. , 2016, ACS chemical neuroscience.
[63] B. Castellotti,et al. ASAH1 variant causing a mild SMA phenotype with no myoclonic epilepsy: a clinical, biochemical and molecular study , 2016, European Journal of Human Genetics.
[64] H. Weiner,et al. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation , 2015, Journal of Neuroinflammation.
[65] S. Finkbeiner,et al. Cytoplasmic sphingosine-1-phosphate pathway modulates neuronal autophagy , 2015, Scientific Reports.
[66] M. Spedding,et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase , 2015, Human molecular genetics.
[67] M. Ratajczak,et al. Pharmacological Elevation of Circulating Bioactive Phosphosphingolipids Enhances Myocardial Recovery After Acute Infarction , 2015, Stem cells translational medicine.
[68] R. Sidman,et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis , 2015, Proceedings of the National Academy of Sciences.
[69] S. Nasoohi,et al. Sphingosin-1-phosphate Receptor 1: a Potential Target to Inhibit Neuroinflammation and Restore the Sphingosin-1-phosphate Metabolism , 2015, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[70] G. Semenkova,et al. Free-radical Destruction of Sphingolipids Resulting in 2-hexadecenal Formation , 2015, Lipid insights.
[71] S. Côté,et al. Reduced Activity of Sphingosine-1-Phosphate Lyase Induces Podocyte-related Glomerular Proteinuria, Skin Irritation, and Platelet Activation , 2015, Toxicologic pathology.
[72] J. Strosznajder,et al. The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson's disease. , 2014, Folia neuropathologica.
[73] J. Cebon,et al. Sphingosine‐1‐phosphate lyase is expressed by CD68+ cells on the parenchymal side of marginal reticular cells in human lymph nodes , 2014, European journal of immunology.
[74] C. Beerli,et al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. , 2014, Journal of medicinal chemistry.
[75] P. Calabresi,et al. FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway , 2014, Journal of Neuroimmunology.
[76] J. Walter,et al. Deficiency of Sphingosine-1-phosphate Lyase Impairs Lysosomal Metabolism of the Amyloid Precursor Protein* , 2014, The Journal of Biological Chemistry.
[77] R. Levenson,et al. Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology. , 2014, Annual review of clinical psychology.
[78] C. Duyckaerts,et al. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer’s disease , 2014, Acta neuropathologica communications.
[79] Russell Pickford,et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis , 2014, Acta neuropathologica communications.
[80] Ping-ping Liu,et al. Sphingosine 1-phosphate (S1P) promotes mitochondrial biogenesis in Hep G2 cells by activating Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) , 2014, Cell Stress and Chaperones.
[81] Holger Jahn,et al. Memory loss in Alzheimer's disease , 2013, Dialogues in clinical neuroscience.
[82] D. Beiser,et al. Inhibition of sphingosine-1-phosphate lyase rescues sphingosine kinase-1-knockout phenotype following murine cardiac arrest. , 2013, Life sciences.
[83] J. Sweatt,et al. Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease , 2013, Neurobiology of Aging.
[84] K. Park,et al. 4-deoxypyridoxine improves the viability of isolated pancreatic islets ex vivo , 2013, Islets.
[85] C. Beerli,et al. Assay to measure the secretion of sphingosine-1-phosphate from cells induced by S1P lyase inhibitors. , 2013, Biochemical and biophysical research communications.
[86] Matthias Mueller,et al. Partial Deficiency of Sphingosine-1-Phosphate Lyase Confers Protection in Experimental Autoimmune Encephalomyelitis , 2013, PloS one.
[87] M. Nimwegen,et al. Topical treatment targeting sphingosine‐1‐phosphate and sphingosine lyase abrogates experimental allergic rhinitis in a murine model , 2013, Allergy.
[88] J. Pfeilschifter,et al. Evidence for a link between histone deacetylation and Ca²+ homoeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts. , 2012, The Biochemical journal.
[89] Ashok Kumar,et al. The sphingolipid degradation product trans-2-hexadecenal forms adducts with DNA. , 2012, Biochemical and biophysical research communications.
[90] E. Bertini,et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. , 2012, American journal of human genetics.
[91] O. Cuvillier,et al. First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer , 2012, Molecular Cancer Therapeutics.
[92] M. L. Lachenmayer,et al. Disrupted Autophagy Leads to Dopaminergic Axon and Dendrite Degeneration and Promotes Presynaptic Accumulation of α-Synuclein and LRRK2 in the Brain , 2012, The Journal of Neuroscience.
[93] P. Bruni,et al. Sphingosine 1-phosphate stimulates proliferation and migration of satellite cells: role of S1P receptors. , 2012, Biochimica et biophysica acta.
[94] S. Haggarty,et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain , 2012, Nature.
[95] D. Rubinsztein,et al. Mechanisms of Autophagosome Biogenesis , 2012, Current Biology.
[96] H. Hartung,et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. , 2012 .
[97] Yuan Yuan,et al. Loss of Sphingosine Kinase 1/S1P Signaling Impairs Cell Growth and Survival of Neurons and Progenitor Cells in the Developing Sensory Ganglia , 2011, PloS one.
[98] J. Jankovic,et al. Resveratrol-Activated AMPK/SIRT1/Autophagy in Cellular Models of Parkinson's Disease , 2011, Neurosignals.
[99] Ashok Kumar,et al. The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. , 2011, Cellular signalling.
[100] J. Trojanowski,et al. BACE1 Activity Is Modulated by Cell-Associated Sphingosine-1-Phosphate , 2011, The Journal of Neuroscience.
[101] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[102] Sparsh Gupta,et al. Fingolimod (FTY720): First approved oral therapy for multiple sclerosis , 2011, Journal of pharmacology & pharmacotherapeutics.
[103] D. Swandulla,et al. Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism , 2011, Cell Death and Differentiation.
[104] A. Borowsky,et al. S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. , 2011, American journal of physiology. Heart and circulatory physiology.
[105] D. C. Simpson,et al. Sphingosine‐1‐phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[106] S. Milstien,et al. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy , 2011, Cell Death and Differentiation.
[107] G. Prestwich,et al. Characterization of sphingosine-1-phosphate lyase activity by electrospray ionization-liquid chromatography/tandem mass spectrometry quantitation of (2E)-hexadecenal. , 2011, Analytical biochemistry.
[108] K. Kain,et al. S1P Is Associated with Protection in Human and Experimental Cerebral Malaria , 2011, Molecular medicine.
[109] M. Ohno,et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. , 2011, Brain : a journal of neurology.
[110] Alan G. E. Wilson,et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). , 2010, Journal of medicinal chemistry.
[111] M. Grütter,et al. Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. , 2010, Structure.
[112] R. Proia,et al. Sphingosine 1-Phosphate Lyase Deficiency Disrupts Lipid Homeostasis in Liver* , 2010, The Journal of Biological Chemistry.
[113] M. Maceyka,et al. Extracellular and intracellular actions of sphingosine-1-phosphate. , 2010, Advances in experimental medicine and biology.
[114] C. Bauvy,et al. Experimental Therapeutics , Molecular Targets , and Chemical Biology Disruption of Sphingosine 1-Phosphate Lyase Confers Resistance to Chemotherapy and Promotes Oncogenesis through Bcl-2 / Bcl-xL Upregulation , 2009 .
[115] Cheng Luo,et al. Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate , 2009, Science.
[116] Ashok Kumar,et al. Lyase to live by: Sphingosine phosphate lyase as a therapeutic target , 2009, Expert opinion on therapeutic targets.
[117] Cihan Çetin,et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. , 2009, Nature chemical biology.
[118] Alan G. E. Wilson,et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. , 2009, Journal of medicinal chemistry.
[119] R. Proia,et al. Subcellular Origin of Sphingosine 1-Phosphate Is Essential for Its Toxic Effect in Lyase-deficient Neurons* , 2009, Journal of Biological Chemistry.
[120] H. Meng,et al. Differential expression of sphingosine‐1‐phosphate receptors 1‐5 in the developing nervous system , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.
[121] P. Dolan,et al. Histone deacetylase 6 interacts with the microtubule‐associated protein tau , 2008, Journal of neurochemistry.
[122] Yusuf A. Hannun,et al. Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.
[123] J. Cyster,et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. , 2008, Immunity.
[124] T. Ueno,et al. LC3 and Autophagy. , 2008, Methods in molecular biology.
[125] E. Persohn,et al. Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.
[126] E. Clementi,et al. Sphingosine 1‐Phosphate Mediates Proliferation and Survival of Mesoangioblasts , 2007, Stem cells.
[127] F. Hsu,et al. Redirection of sphingolipid metabolism toward de novo synthesis of ethanolamine in Leishmania , 2007, The EMBO journal.
[128] T. Ohmori,et al. Essential Roles of Sphingosine 1‐Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury , 2007, Stem cells.
[129] C. S. Raymond,et al. PDGF signaling specificity is mediated through multiple immediate early genes , 2007, Nature Genetics.
[130] M. Salvadori,et al. FTY720 versus MMF with Cyclosporine in de novo Renal Transplantation: A 1‐Year, Randomized Controlled Trial in Europe and Australasia , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[131] A. Borowsky,et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer , 2006, Proceedings of the National Academy of Sciences.
[132] M. Vasko,et al. Intracellular sphingosine 1‐phosphate mediates the increased excitability produced by nerve growth factor in rat sensory neurons , 2006, The Journal of physiology.
[133] G. Russ,et al. FTY720/Cyclosporine Regimens in De Novo Renal Transplantation: A 1‐Year Dose‐Finding Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[134] H. Kretzschmar,et al. Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein , 2006, The Journal of Neuroscience.
[135] Masaaki Komatsu,et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice , 2006, Nature.
[136] Hideyuki Okano,et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.
[137] L. Riboni,et al. Sphingosine‐1‐phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi‐protein‐coupled receptors , 2006, Glia.
[138] B. Kinzel,et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. , 2006, Blood.
[139] H. Matsuyuki,et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. , 2006, Cellular & molecular immunology.
[140] R. Proia,et al. Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.
[141] K. Chiba. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. , 2005, Pharmacology & therapeutics.
[142] B. Oskouian,et al. The Immune Modulator FTY720 Inhibits Sphingosine-1-phosphate Lyase Activity* , 2005, Journal of Biological Chemistry.
[143] Ying Xu,et al. Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients , 2005, Science.
[144] P. Bruni,et al. Sphingosine 1‐phosphate regulates myogenic differentiation: a major role for S1P2 receptor , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[145] R. Proia,et al. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit , 2005, The Journal of experimental medicine.
[146] A. Kihara,et al. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5'-phosphate binding domain exposed to the cytosol. , 2004, Biochemical and biophysical research communications.
[147] Amadeu Llebaria,et al. Specificity of the Dihydroceramide Desaturase Inhibitor N-[(1R,2S)-2-Hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in Primary Cultured Cerebellar Neurons , 2004, Molecular Pharmacology.
[148] S. Payne,et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension , 2004, The Journal of cell biology.
[149] R. Proia,et al. Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration* , 2004, Journal of Biological Chemistry.
[150] M. Moskowitz,et al. Sphingosine‐1‐phosphate induces proliferation and morphological changes of neural progenitor cells , 2004, Journal of neurochemistry.
[151] R. Proia,et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.
[152] S. Payne,et al. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2 , 2003, FEBS letters.
[153] K. Budde,et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.
[154] J. Vermeesch,et al. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). , 2000, Biochimica et biophysica acta.
[155] T. Hanano,et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. , 2000, Journal of medicinal chemistry.
[156] P. Dash,et al. Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes , 1999, Neuroscience.
[157] S. Chueh,et al. Prophylaxis of acute renal allograft rejection using FTY720 in combination with subtherapeutic doses of cyclosporine. , 1999, Transplantation.
[158] M. Bradbury,et al. The immunomodulatory compound 2‐acetyl‐4‐tetrahydroxybutyl imidazole causes sequestration of lymphocytes in non‐lymphoid tissues , 1997, Immunology and cell biology.
[159] S. Spiegel,et al. Involvement of Sphingosine 1-Phosphate in Nerve Growth Factor-Mediated Neuronal Survival and Differentiation , 1997, The Journal of Neuroscience.
[160] M. Reale,et al. Generation of TNF alpha, IFN gamma, IL-6, IL-4 and IL-10 in mouse serum from trichinellosis: effect of the anti-inflammatory compound 4-deoxypyridoxine (4-DPD). , 1996, Immunology letters.
[161] T. Fujita,et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .
[162] T. Okumoto,et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. , 1994, The Journal of antibiotics.
[163] Stephen P. Miller,et al. Synthesis of an inhibitor of sphingosine-1-phosphate lyase , 1994 .
[164] A. D. de Groot,et al. The effect of pyridoxine on the number of lymphocytes in the blood of rats fed caramel colour (III). , 1988, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[165] J. Greef,et al. 2-Acetyl-4(5)-(1,2,3,4-tetrahydroxybutyl)imidazole: detection in commercial caramel color III and preparation by a model browning reaction , 1985 .
[166] W. Stoffel,et al. Chemistry and biochemistry of 1-desoxysphinganine 1-phosphonate (dihydrosphingosine-1-phosphonate). , 1974, Chemistry and physics of lipids.
[167] E. P. Kennedy,et al. The function of cytidine coenzymes in the biosynthesis of phospholipides. , 1956, The Journal of biological chemistry.